For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Patients to be hit hard after too-little, too-late 4% offer to general practice
Patients to be hit hard after too-little, too-late 4% offer to general practice

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published on 2 July 2024.
From Barbara: I love it when Fiona Cassie sets her mind on sorting out figures. This year’s paltry 4 per cent capitation funding increases came with a rider to “go forth and charge patients”. She chased up details on funding increases for all PHO funding streams
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.